Amsterdam UMC
Verified site
Amsterdam, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study aims to compare the effectiveness of a new treatment called teclistamab with other existing treatments. These existing treatments include combinations of medications such as pomalidomide, bortezomib, and dexamethasone, as well as carfilzomib and dexamethasone. Pomalidomide is also known by its code name CC-4047, and carfilzomib is sometimes referred to as PR-171. The study will also involve a placebo group for comparison.
The purpose of the study is to determine which treatment is more effective for patients with relapsed or refractory multiple myeloma, meaning the cancer has returned or is not responding to previous treatments. Participants in the study will receive one of the treatments mentioned above, and their progress will be monitored over time. The study will help researchers understand how well these treatments work in managing the disease and improving patient outcomes.
Participants will be randomly assigned to receive either the new treatment or one of the existing treatment combinations. The study will take place over a period of time, during which participants will be regularly assessed to track their response to the treatment. The main goal is to see how long patients can live without the disease getting worse, known as progression-free survival. This study is an important step in finding better ways to treat multiple myeloma and improve the quality of life for those affected by this condition.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
5 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Amsterdam, The Netherlands
Siena, Italy
Leuven, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication being studied for its potential to treat multiple myeloma, a type of blood cancer. It is being tested to see how well it works on its own in patients who have already tried other treatments.
is a medication used to treat multiple myeloma. It works by helping the immune system attack cancer cells and by stopping the growth of these cells.
is a medication that treats multiple myeloma by interfering with the growth of cancer cells, eventually destroying them. It is often used in combination with other medications.
is a type of steroid that helps reduce inflammation and is used in combination with other medications to treat multiple myeloma. It can help improve the effectiveness of cancer treatments.
is a medication used to treat multiple myeloma by blocking certain proteins in cancer cells, which leads to their death. It is often used when other treatments have not been successful.
Teclistamab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its effectiveness in treating relapsed or refractory multiple myeloma, a type of blood cancer. The medication works by targeting specific proteins on the surface of cancer cells, helping the immune system to recognize and destroy these cells. Teclistamab is classified as a monoclonal antibody, a type of drug designed to interact with specific targets in the body.
Pomalidomide is taken orally in the form of capsules. It is an established treatment for multiple myeloma, particularly in patients who have not responded to other therapies. The drug works by modulating the immune system and inhibiting the growth of cancer cells. Pomalidomide belongs to a class of medications known as immunomodulatory agents.
Bortezomib is administered via injection, either under the skin or into a vein. It is widely used in the treatment of multiple myeloma and certain types of lymphoma. The medication functions by blocking the action of proteasomes, which are structures inside cells that break down proteins, leading to cancer cell death. Bortezomib is classified as a proteasome inhibitor.
Dexamethasone is available in oral tablet form or as an injection. It is used in combination with other medications to treat multiple myeloma and other conditions. The drug works by reducing inflammation and suppressing the immune response. Dexamethasone is a corticosteroid, a type of steroid hormone.
Carfilzomib is given as an injection into a vein. It is used for treating multiple myeloma, especially in patients who have not responded to other treatments. The drug acts by inhibiting proteasomes, leading to the accumulation of proteins in cancer cells and causing their death. Carfilzomib is also classified as a proteasome inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.